Company / R&D Expense
Elanco R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$368.0M
FY2025
5-year range
$321.0M / $369.0M
FY2021-FY2025
Trend
+7.0%
vs FY2024
Sector context
#46 of 210
Health Care
What the data says
Elanco's r&d expense of $368M is higher than 78% of companies in the Health Care sector (FY2025). R&D Expense has increased for 3 consecutive years, from $321M in FY2022 to $368M in FY2025.
Based on SEC 10-K filings.
$368M in FY2025 with a 5-year CAGR of +2.3%. Top quartile in the Health Care sector.
Improved from $327M to $368M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +4.7%
- 5-Year CAGR
- +2.3%
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 210This company $368.0M Sector average $644.1M
▼
-42.9% below sector average
Key checks
Key Insights
- Elanco's r&d expense has grown for 3 consecutive years.
- 5-year CAGR of +2.3%, indicating consistent growth.
- In FY2025, r&d expense increased 7.0% year-over-year.
- Ranks #46 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $368.0M | +7.0% |
| FY2024 | $344.0M | +5.2% |
| FY2023 | $327.0M | +1.9% |
| FY2022 | $321.0M | -13.0% |
| FY2021 | $369.0M | +12.2% |
| FY2020 | $329.0M | +21.9% |
| FY2019 | $270.0M | +9.5% |
| FY2018 | $246.6M | -2.0% |
| FY2017 | $251.7M | -5.3% |
| FY2016 | $265.8M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026